Anupam Rasayan India Limited — PPTs, 23-05-2025: Investor Presentation

1. Financial Highlights:

Consolidated total revenue declined 4% YoY to ₹1,448 Cr in FY25, with Q4 rebounding 31% QoQ to ₹506 Cr. EBITDA remained steady at ₹412 Cr for the year (28% margin) and improved to 30% in Q4. PAT slipped slightly to ₹160 Cr (11% margin) for FY25 but surged 55% QoQ to ₹63 Cr in Q4, driven by operational efficiencies and better product mix. Standalone revenue fell 21% YoY to ₹909 Cr, yet EBITDA margin rose to 31%. Quarterly standalone PAT advanced 35% QoQ to ₹38 Cr (11% margin). Cost controls and sustained R&D spending supported margin resilience despite a soft H1 FY25 market.

2. Strategic Initiatives & Growth Drivers:

Anupam expanded its pharma and polymer portfolios, commercializing six new molecules and advancing over 95 in R&D/pilot stages. Focus remains on high-value custom intermediates for a pharma TAM of ~$15B and polymer TAM of ~$10B with 4-5% CAGR. Capex of ~₹55 Cr over five years boosted R&D and manufacturing capacity, which has doubled in three years. The ~26% acquisition in Tanfac secures supply of key fluorination raw materials, strengthening presence in high-margin fluorination chemistries.

3. Business Developments:

Multiple long-term contracts and LOIs total ₹1,464 Cr, including a ₹300 Cr LOI with Elementium for battery chemicals. The Tanfac stake complements Anupam’s specialty fluoride chemicals business, with combined FY25 revenues over ₹2,000 Cr. Enhanced fluorination capabilities position the company as a single Asian supplier of select high-value molecules to global pharma, agrochemical, and polymer MNCs.

4. Market Position & Competitive Advantage:

With 41 years of expertise, a diverse portfolio of 79 complex molecules, and 75+ clients (including 31 MNCs), Anupam benefits from integrated supply chains, strong R&D, and backward integration. Leadership in fluorination chemistry and strong industry partnerships create differentiation. Local manufacture of niche specialty chemicals supports global import substitution trends, reinforcing scale advantages.

5. Investor Implications:

Q4 rebound indicates positive growth potential fueled by new product launches and strategic expansions in pharma, polymer, and fluorination chemistries. Backward integration lowers supply risk and aids margin sustainability. A robust order book and pipeline underpin scalable future revenues. Execution risks around LOI commercialization and macro factors exist, but overall Anupam is well-positioned for innovation-led, profitable growth.